Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429975 | 0.89 | SAT1 (0.42) | SAT1LPAR3LPAR2LPAR1S1PR2 | |
| SCHEMBL3429864 | 0.86 | SAT1 (0.38) | SAT1LPAR3LPAR2LPAR1SMN1; SMN2 | |
| SCHEMBL3429508 | 0.85 | SAT1 (0.50) | SAT1LPAR3LPAR2LPAR1S1PR2 | |
| SCHEMBL30143641 | 0.78 | SAT1 (0.45) | SAT1LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL18359267 | 0.77 | MEN1 (0.43) | SMN1; SMN2MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL19860988 | 0.77 | MEN1 (0.43) | SMN1; SMN2MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL12733319 | 0.77 | LPAR3 (0.50) | LPAR3LPAR2LPAR1MEN1KMT2A | |
| SCHEMBL3429685 | 0.77 | LPAR3 (0.39) | SAT1LPAR3LPAR2LPAR1SMN1; SMN2 | |
| SCHEMBL1627450 | 0.76 | MEN1 (0.55) | LPAR3LPAR2LPAR1MEN1KMT2A | |
| SCHEMBL125343 | 0.76 | MEN1 (0.55) | LPAR3LPAR2LPAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | SAT1 2675/4885LPAR3 3825/4885LPAR2 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.